Plain-English translation of NCT06046079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how people using HIV prevention medications—either a long-acting injection called LAI-PrEP or a daily pill—connect with other health and support services in their community. This study will compare people currently taking the medication with those who have never used it, to see if the medication helps people access sexual health screenings, mental health care, substance use treatment, and social support services like food assistance or housing help.
Many people at risk for HIV don't know about or use all the health and social services available to them. Researchers believe that when people start this medication, it might open a door to connect them with additional care they need.
You likely qualify if…
You likely don't qualify if…
You will be part of a 12-month study where researchers will track your health and social service use over time. This likely involves sharing information about your medication use, your visits to health clinics and counseling services, and your use of social support resources. The study is being run by a community-based organization in Washington DC that supports people's health and well-being.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Enrollment target
~100 participants
Started
August 2023
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
DeMarc Hickson, PhD
Us Helping Us, People Into Living, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.